GS-9669

Phase 2Small molecule

Gilead

GS-9669 is one of 68 small molecule programs targeting Chronic Hepatitis. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Chronic HepatitisActive, not recruiting

Chronic Hepatitis C Virus InfectionActive, not recruiting

Chronic HepatitisPhase 2

Active, not recruiting

Chronic Hepatitis C Virus InfectionPhase 1

Active, not recruiting

Competition

Competitive Landscape

624 competitors in Chronic Hepatitis

#DrugCompanyPhaseTrials

PEG-Intron

Merck & Co.

Preclinical

43 2

Sovaldi

Gilead

Preclinical

34 3

Virazole

CConrado Roberto Hoffmann Filho

Preclinical

199 4

Incivek

Vertex Pharmaceuticals

Preclinical

10 5

Intron a

Sanofi

Preclinical

7 6

Roferon-a

Roche

Preclinical

3 7

Medrol

Pfizer

Preclinical

1 8

Dasabuvir

AbbVie

Preclinical

7 9

GS-9669

Gilead

Phase 2

1 10

SOF/VEL

Gilead

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

HCV Infection1 trial

Ledipasvir/Sofosbuvir Fixed-Dose Combination With Ribavirin or GS-9669 in Subjects With Chronic Genotype 1 HCV Infection

Completed· Gilead logo

Gilead·Phase 2·NCT01984294·101 enrolled

Chronic Hepatitis C Virus Infection1 trial

Safety, Tolerability, Pharmacokinetics and Antiviral Activity of GS-9669 in Subjects With Chronic Hepatitis C Virus Infection

Completed· Gilead logo

Gilead·Phase 1·NCT01431898·82 enrolled

Treatment1 trial

Open-Labeled Study of PSI-7977 and RBV With and Without PEG-IFN in Treatment-Naïve Patients With HCV GT2 or GT3

Completed· Gilead logo

Gilead·Phase 2·NCT01260350·292 enrolled

Efficacy and Safety1 trial

Efficacy and Safety of Sofosbuvir Containing Regimens for the Treatment of Chronic HCV Infection in Participants With Chronic Genotype 1, 2, 3, or 6 HCV Infection

Completed· Gilead logo

Gilead·Phase 2·NCT01826981·359 enrolled

Chronic Hepatitis1 trial

Combination Therapy for Chronic Hepatitis C Infection

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT01805882·229 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for GS-9669. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — GS-9669 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for GS-9669. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Gilead company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: Gilead

GS-9669

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

HCV Infection1 trial

Chronic Hepatitis C Virus Infection1 trial

Treatment1 trial

Efficacy and Safety1 trial

Chronic Hepatitis1 trial

References

Drug Info

Quick Facts

Related News